Locust Walk Insights
LOCUST WALK INSIGHTS
Strategic Implications of COVID-19 on Biopharma
These are challenging times for governments, public health administrations and the financial markets. While each biopharma company's primary concern is the health and safety of its team members, the industry also a responsibility to the world to take an active role in...
Deal Theory: a Biopharma Deal Maker’s Approach to Maximizing Strategic Partnerships
We are pleased to present this whitepaper to you, Deal Theory: A Biopharma Deal Maker’s Approach to Maximizing Strategic Value, to share some best practices that will help companies achieve better results through the right partnership transactions.
Deal Makers of Japan, Volume 1
Locust Walk has been active in Asia, in particular, Japan for nearly half of the firm’s history and we are deeply rooted in the market. We have advised on more than a dozen transactions during our history in Japan and have successfully helped deal making between US/EU...
2019 Year End Review Biopharma Report
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2019 Annual Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
2019 Medtech Year End Review Report
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Medtech 2019 Annual Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the medtech deal...
Q3 2019 Report: Global Trends in Medtech Transactions
Every quarter, Locust Walk's medtech team compiles the latest statistics and trends on strategic medtech transactions and financings, with a focus on upcoming trends.
Q3 2019 Global Trends in Biopharma Transactions
At the end of each quarter, our biopharma team here at Locust Walk reviews the global trends in biopharma transactions with an eye on future trends.
Whitepaper Download: Inside Out
Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing validity.
My (National Lampoon’s) European Vacation
I recently returned from a month in Europe as part of our effort to expand Locust Walk's European practice. It was an amazing trip meeting great people and learning valuable lessons. While I did not visit all countries for business, I thought I'd share a...
Financing overhang or hangover: The impact on partnerships for public biotech companies
Overview Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including, but not limited to, advancement of the asset(s) in...
Q2 2019 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2019 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal...
Q2 2019: Global Trends in Medtech Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2019 Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the life sciences deal...
Brian Coleman of Locust Walk to Moderate Panel at BioEquity Europe: Drawing Your Financing Roadmap
Brian Coleman, Locust Walk's Managing Director, Global Head of Financing and Sales will be moderating the panel, Drawing Your Financing Roadmap, at BioEquity Europe: Faced with an expanding range of financing options, early stage biotech executives must figure out how...
Global Business Reports Interview with Geoff Meyerson, CEO & Co-Founder of Locust Walk
Special Report on the U.S. Biopharmaceuticals Industry 2019Selected quotes from the interview with Geoff Meyerson, CEO and Co-Founder of Locust WalkLarge pharma is veering towards bolt-on acquisition deals. How is this impacting the transactions you are...
Greed is Bad: Why Defendable Commercial Assessments are Better Than Pie in the Sky
Clear, data-based financial assumptions are essential to driving a successful deal process. In a previous post, The Value of a Commercial Assessment in Supporting a Transaction, I discussed the main ways that a well-done commercial assessment...